Efficacy of argatroban in critically ill patients with heparin resistance: A retrospective analysis

Seminars in Thrombosis and Hemostasis

Volumn 41, Issue 1, 2015, Pages 61-67

  Treichl, Benjamin ^a   Bachler, Mirjam ^a   Lorenz, Ingo ^a   Friesenecker, Barbara ^a   Oswald, Elgar ^a   Schlimp, Christoph J ^b   Pedross, Florian ^a   Fries, Dietmar ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR EXPERIMENTAL AND CLINICAL TRAUMATOLOGY   (Austria)

Author keywords

argatroban; heparin resistance; prophylactic anticoagulation; thrombosis

Indexed keywords

ARGATROBAN; FRESH FROZEN PLASMA; HEPARIN; ANTICOAGULANT AGENT; ANTITHROMBIN III; ANTITHROMBOCYTIC AGENT; PIPECOLIC ACID DERIVATIVE;

ADULT; ALTERNATIVE MEDICINE; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD; BLOOD LEVEL; CLINICAL ARTICLE; CRITICALLY ILL PATIENT; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SUBSTITUTION; ERYTHROCYTE; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LOW DRUG DOSE; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PHYSIOLOGY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOEMBOLISM; THROMBOSIS PREVENTION; CRITICAL ILLNESS; DRUG RESISTANCE; METABOLISM;

ANTICOAGULANTS; ANTITHROMBIN III; CRITICAL ILLNESS; DRUG RESISTANCE; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; PIPECOLIC ACIDS; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES;

EID: 84928487351     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0034-1398382     Document Type: Article

References (18)

1. Fries D. Anticoagulation in critically ill patient [in German]. Wien Med Wochenschr: 2009; 159 19-20 487 491
2. Dellinger R. P., Levy M. M., Rhodes A., et al. Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med: 2013; 39 2 165 228
3. Cook D., Douketis J., Crowther M. A., Anderson D. R.; VTE in the ICU Workshop Participants. The diagnosis of deep venous thrombosis and pulmonary embolism in medical-surgical intensive care unit patients. J Crit Care: 2005; 20 4 314 319
4. Harris L. M., Curl G. R., Booth F. V., Hassett J. M. Jr, Leney G., Ricotta J. J. Screening for asymptomatic deep vein thrombosis in surgical intensive care patients. J Vasc Surg: 1997; 26 5 764 769
5. Joynt G. M., Kew J., Gomersall C. D., Leung V. Y., Liu E. K. Deep venous thrombosis caused by femoral venous catheters in critically ill adult patients. Chest: 2000; 117 1 178 183
6. Marik P. E., Andrews L., Maini B. The incidence of deep venous thrombosis in ICU patients. Chest: 1997; 111 3 661 664
7. Anderson J. A., Saenko E. L. Heparin resistance. Br J Anaesth: 2002; 88 4 467 469
8. Levy J. H. Heparin resistance and antithrombin: should it still be called heparin resistance? J Cardiothorac Vasc Anesth: 2004; 18 2 129 130
9. Rodríguez-López J. M., del Barrio E., Lozano F. S., Muriel C. Does preoperative level of antithrombin III predict heparin resistance during extracorporeal circulation? Anesth Analg: 2008; 107 4 1444 1445
10. Maurin N. Heparin resistance and antithrombin deficiency [in German]. Med Klin (Munich): 2009; 104 6 441 449
11. Young E., Prins M., Levine M. N., Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost: 1992; 67 6 639 643
12. Levine S. P., Sorenson R. R., Harris M. A., Knieriem L. K. The effect of platelet factor 4 (PF4) on assays of plasma heparin. Br J Haematol: 1984; 57 4 585 596
13. Hirsh J., van Aken W. G., Gallus A. S., Dollery C. T., Cade J. F., Yung W. L. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation: 1976; 53 4 691 695
14. Link A., Girndt M., Selejan S., Mathes A., Böhm M., Rensing H. Argatroban for anticoagulation in continuous renal replacement therapy. Crit Care Med: 2009; 37 1 105 110
15. Yamada K., Tsuji H., Kimura S., et al. Effects of argatroban and heparin on thrombus formation and tissue plasminogen activator-induced thrombolysis in a microvascular thrombosis model. Thromb Res: 2003; 109 1 55 64
16. Warkentin T. E., Greinacher A., Koster A., Lincoff A. M.; American College of Chest Physicians. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest: 2008; 133 (6, Suppl): 340S 380S
17. Alban S. Adverse effects of heparin. Handbook Exp Pharmacol: 2012; 207 211 263
18. Saugel B., Phillip V., Moessmer G., Schmid R. M., Huber W. Argatroban therapy for heparin-induced thrombocytopenia in ICU patients with multiple organ dysfunction syndrome: a retrospective study. Crit Care: 2010; 14 3 R90